Physiomics wins new contract with Numab Therapeutics

(Sharecast News) - AIM-listed biotech Physiomics has announced a new contract with client Numab Therapeutics to help development activities for the latter's oncology pipeline.

The contract, which is set to begin this month and last sometime in the third quarter, will see Physiomics develop a so-called mechanistic pharmacokinetic-pharmacodynamic modelling framework to support Numab in its proof-of-concept work for a new programme.

Physiomics will interpret data, optimise experimental design and development strategy, and inform key go/no-go decision-making for Numab, it said.

"We are thrilled to extend our collaboration with Numab Therapeutics to provide insights that can support robust proof-of-concept decision-making for this early oncology programme," said Physiomics chief executive Peter Sargent.

The stock was up 1.8% at 0.51p by 1456 BST.

See the latest RNS on Investegate.

No financial details regarding the contract were published.

Physiomics